Close

Anti-gag (SLYNTVATL) TCR, pGMT7 (TCR-L019)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-gag T cell receptor (TCR) is constructed for the engineering of T cell to target HIV gag. The T cells are genetically modified through transduction with a retroviral vector expressing gag-specific T cell receptor. And the vector product was designed for the treatment of ADIS.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • gag
  • Target Species
  • HIV
  • Epitope
  • SLYNTVATL
  • Format
  • Non-modified TCR
  • Allele
  • HLA-A*0201
  • Targeting Diseases
  • ADIS
  • Vector Name
  • pGMT7
  • Vector Length
  • 3111bp
  • Vector Type
  • retroviral vector
  • Host Species
  • Human

Target

  • Official Symbol
  • gag
  • Introduction
  • HIV1 p15(Gag) and its protease cleavage products, nucleocapsid protein p7 and p6, are believed to play a major role in viral infectivity and assembly during the early and late stages of retroviral life cycle. p15 is frequently recognized by HIV1-specific CD8+T cells in natural HIV1 infection and may be an important target for the design of future HIV1 vaccines.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-gag (SLYNTVATL) T Cell Receptor, pGMT7 (TCR-L019). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.